NCT03831984

Topical Bromfenac for Intraoperative Miosis and Pain Reduction

Topical 0,09% Bromfenac for Intraoperative Miosis and Pain Reduction in Femtosecond Laser-assisted Cataract Surgery

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Hospital de La Luz · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

To evaluate the effect of bromfenac ophthalmic solution 0.09% for reduction of intraoperative miosis and pain in patient who have undergone femtosecond laser-assisted cataract surgery.

Detailed description

This prospective cross-sectional randomized clinical study included 60 patients with senile cataract in the absence of significant ocular comorbidity. The patients received 0.09% bromfenac ophthalmic solution or control placebo twice a day for 3 days before surgery. Pupil diameter was measured at the initiation and finalization of femtosecond laser-assisted cataract surgery and pain quantification was assessed by analogous pain scale at one day follow-up.

Conditions

• Cataract

Interventions

Type	Name	Description
DRUG	0,09% Bromfenac	topical 0,09% Bromfenac, one drop twice daily 3 days before surgery
DRUG	0,1% sodium hyaluronate	topical 0,1% sodium hyaluronate, one drop twice daily 3 days before surgery

Timeline

• Start date: 2018-03-01
• Primary completion: 2018-11-30
• Completion: 2019-03-30
• First posted: 2019-02-06
• Last updated: 2019-02-06

Locations

1 site across 1 country: Mexico